This company provides an integrated lab platform that automates 3D cell culture workflows, including planning, execution, and analysis. The system delivers high-quality, reproducible experimental outcomes necessary for advancing organoid and spheroid research. This automation enhances the predictive power of tissue cultures for drug screening and disease modeling.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional 3D cell culture processes for medical research are often manual, limiting scalability, traceability, and reproducibility in experiments. These manual methods are time-consuming and costly, hindering efficient drug development and screening.
Solution
Mo:re provides a robotic and software platform designed to automate 3D cell culture processes, enhancing the efficiency and reliability of medical research. The platform offers standardized lab protocols and AI-assisted cultivation to ensure cell survival and standardization, even during long-term studies. Automation of experiment steps reduces the need for manual intervention, freeing up researchers' time and minimizing errors. The system provides unprecedented traceability and reproducibility, which is crucial for research publications and regulatory approval. The platform's capabilities facilitate faster and cheaper medical research through AI-assisted 3D cell culture models.
Target Audience
The primary target audience includes researchers in cell therapy, drug development, drug screening, genetic engineering, disease modeling, and cell-to-cell interaction studies.
Features
- Automated execution of standardized 3D cell culture protocols.
- AI-assisted cultivation processes to optimize cell survival and standardization.
- Remote operation and online monitoring capabilities.
- Automated analysis of experimental results delivered directly to the user.
- Compact and easy-to-use robotic platform.
- Single-click access to standardized lab protocols.
- Batch processing capabilities for high-throughput experimentation.